• Dry Cracked Skin
  • General Dermatology
  • Impetigo
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Surgery
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Inflamed Skin

In Review: Looking Back at Some of 2023's Largest Studies in Dermatology


Dermatology Times is reviewing some of the newest and largest studies coming out of this year.

SMAK_Photo/Adobe Stock
SMAK_Photo/Adobe Stock


Christopher Bunick, MD, PhD, Previews Recently Published Sarecycline Study to be Presented at AAD

Data published in Nucleic Acids Research builds on previous studies investigating the benefits of sarecycline for acne vulgaris compared to other antibiotics.

Research Finds Dermatology Visits for Acne Higher in Adult Female Patients

Yale School of Medicine researchers found tetracycline-class antibiotics were the most prescribed acne treatment for adult female patients between 2002 and 2016.


Steven Dayan, MD, FACS: Prioritizing Patient Satisfaction in Cosmetic Dermatology

Steven Dayan, MD, FACS, first author behind a recent study involving high rates of patient satisfaction following treatment with botulinum toxin, discusses the importance of placing patient satisfaction at the forefront of cosmetic dermatology.

Phase 3 Trial Data Highlights Efficacy of OnabotulinutoxinA in Platysma Prominence

Sachin Shridharani, MD, discusses the results of a recent Allergan Aesthetics study exploring the efficacy of onabotulinumtoxinA in treating platysma prominence.

Path to Care Study Shows Significant Cost Consideration Disparities Among Cosmetic Dermatology Patients

Greg Pierce of Synchrony discusses CareCredit's Path to Care study and its findings related to cost and finance considerations for cosmetic dermatology patients.


New Study Shows Prevalence of Alopecia Areata in People of Color

The findings of this cross-sectional study indicate alopecia areata, alopecia totalis, and alopecia universalis is more common in people of color, particularly Asian Americans.


New Investigational Topical Peptide Offers Promising Eczema Treatment

Cytokine-expressing genes were silenced in a recent Vanderbilt University Medical Center study.

How Heavy Traffic Can Increase the Risk of Atopic Dermatitis

Researchers link proximity to heavy traffic and risk of atopic dermatitis in new study.

Ruxolitinib Cream Provides Substantial, Sustained Itch Relief in AD Patients

A single-site study involving an adult cohort with atopic dermatitis saw significant itch improvement.

ADORING 1 Study Reveals Promising Results for Tapinarof in Atopic Dermatitis

New data from Dermavant showed high levels of efficacy and statistical significance for the topical cream, which is expected to have an sNDA on file with the US FDA in early 2024.

New Positive Topline Results From Ruxolitinib Phase 3 Trial for Pediatric AD

The TRuE-AD3 study met its primary endpoint of IGA-TS improvement from baseline at week 8.

Hidradenitis Suppurativa

Results of Phase 2 Study Evaluating Hidradenitis Suppurativa Drug Announced

Incyte announces that its study of povorcitinib revealed sustained and durable efficacy after 1 year.

Treatment Disparities in Patients of Color With Hidradenitis Suppurativa

A key factor associated with delayed diagnosis for non-White patients is the lack of awareness that their symptoms are associated with a treatable medical condition, according to Oma Agbai, MD, and Lisa Nyanda-Manalo, MD.

Oral Orismilast Shows Clinically Relevant Improvement In Patients With Moderate To Severe Hidradenitis Suppurativa

The OSIRIS open-label study resulted in a reduction of pain and improvement in quality of life for participants.

Izokibep Fails in Phase 2b/3 Hidradenitis Suppurativa Trial

The IL-17A inhibitor did not meet its phase 2b/3 clinical trial primary end point.


Positive Topline Results Announced for Oral Orismilast for Treatment of Psoriasis

Union therapeutics is also developing the drug for treatment of atopic dermatitis and hidradenitis suppurativa.

Study Finds Long-Term Safety and Efficacy for Roflumilast Cream for Chronic Plaque Psoriasis

The year-long study gives insight to the treatment’s efficacy and safety of durability.

Guselkumab, Ustekinumab Led to 2 Years of Sustained Improvements in Patients With Psoriasis

In the PERSIST study, improvements were sustained through week 104.

VISIBLE Study Paves Way for More Equitable Psoriasis Research

The study is the only large-scale dermatologic study to prospectively generate insights into skin conditions among patients of racial and ethnic minority groups.


DFD-29 Achieves Phase 3 Co-Primary and All Secondary Endpoints for Papulopustular Rosacea Treatment

Based on the positive topline phase 3 results, Journey Medical plans to submit a New Drug Application to the FDA in the second half of 2023.

Skin Cancer

Hedgehog Inhibitor Therapy’s Use in Advanced Basal Cell Carcinoma – Does It Work?

A study published in Future Medicine finds consistent use of the treatment is difficult for patients to maintain in a real-world setting.

Oral Vitamin D Supplementation May Lower Melanoma Risk

Researchers were unable to determine a definite correlation.

First Dosing of Patient in Phase 2 Study Evaluating VP-315 for BCC

Verrica Pharmaceuticals is developing a potentially first-in-class oncolytic peptide.


Recent Povorcitinib 2b Study Shows Improved Repigmentation

The investigational oral JAK1 inhibitor showed promising results for vitiligo patients.

High Proportion of Patients With Vitiligo in the US Do Not Receive Treatment, Study Says

A real-world retrospective analysis also found that among patients receiving treatment, most were unlikely to use more than 1 treatment or switch to an alternative treatment during the first year of diagnosis.


GlobalSkin’s GRIDD Study Seeks to Evaluate Global Impact of Skin Diseases

Researchers anticipate that upwards of 10,000 adults with various dermatologic conditions will partake in the study.

Notice any major studies we may have missed in our recap? Email our team at DTEditor@mmhgroup.com.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.